LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic ...

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

A pill version of A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

There’s rarely good news about Alzheimer’s disease, but a failed study may open the door to more research about vascular ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an early end of the trial extension.

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...